DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Stem Cell Transplantation Produces Prolonged Survival With Improved Safety in Patients With AL Amyloidosis
AL amyloidosis is a life-threatening disease related to bone marrow cancer, multiple myeloma. It is caused when a person’s antibody-producing white blood cells (i.e. plasma cells) do not function properly and generate abnormal protein which misfolds to form amyloid fibrils and deposits made of components of antibodies called light chains, which then deposit in various organs of the body.
In the largest study of its kind, researchers from the Boston University/Boston Medical Center Amyloidosis Center have found that HDM/SCT produces prolonged survival with improved safety in patients with AL amyloidosis. Additionally, they have for the first time developed a predictive score to assess event free survival following stem cell transplantation.


Related Content
-
people & placesInternational Myeloma FoundationThe International Myeloma Foundation (IM...
-
people & placesJosephine D. Abraham, MD, MPH, FASNJosephine Abraham is a nephrologist at t...
-
educationA Prospective Phase 2 Trial of Daratumumab in Patients With Previously Treated Systemic Light-Chain AmyloidosisDaratumumab is a human monoclonal anti...
-
people & placesBrent P. Goodman, MDBrent P. Goodman is a neurologist at May...
-
videos & visualsHello, Amy Compilation CDhttps://www.youtube.com/watch?v=U0B8TcsV...
-
videos & visualsAL Amyloidosis Treatment Including Stem Cell Transplantationhttps://www.youtube.com/watch?v=f6kSzKge...
-
educationCase Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.